Dr. Reddy's Laboratories Ltd.

₹1,200

-6 (-0.5%)

DRREDDY Share Price

Pharmaceuticals & Biotechnology

As on August 14, 2026

SectorHealthcare

IndustryPharmaceuticals & Biotechnology

Basic IndustryPharmaceuticals

Market Cap₹ 1,041 Cr

P/E Ratio23.88

Dividend Yield0.67 %

Trendline Performance

We are partnered with TradingView, a global leader in charting and market analysis. Access real-time stock data, explore the powerful Stock Screener , and uncover insights with multiple tools designed for traders.

Unlock Stock of the Month

T&C*

Technicals

Indicators	Value	Signal
5-DMA	1,193.96	Bullish
10-DMA	1,184.14	Bullish
20-DMA	1,174.64	Bullish
50-DMA	1,245.96	Bearish
100-DMA	1,261.86	Bearish
200-DMA	1,257.55	Bearish

Historical Performance

1 Year

-4.8%

3 Years

5 Years

29%

10 Years

99.3%

Shareholding Pattern

Values Analysis

Loading chart...

Profit & Loss

Below figures are in Rs. Crores

Particulars	Mar-2026	Mar-2025	Mar-2024	Mar-2023	Mar-2022
Net Sales	3,37,002	3,26,439	2,80,111	2,46,697	2,15,452
Total Expenditure	2,72,467	2,40,968	2,00,780	1,83,207	1,77,778
Other Income	13,584	10,973	8,943	10,555	4,847
Operating Profit	78,119	96,444	88,274	74,045	42,521
Interest	3,738	2,829	1,711	1,428	958
Depreciation	20,588	17,037	14,700	12,502	11,652
Profit Before Tax	53,927	76,795	72,010	60,485	30,614
Consolidated Net Profit	41,960	56,551	55,779	45,073	21,825
Adjusted EPS	50	68	67	54	26

Compounded Sales Growth

10 Years:16.7

5 Years:12.1

3 Years:6.4

TTM:0.6

Compounded Profit Growth

10 Years:14.5

5 Years:16.5

3 Years:-1.4

TTM:-5.8

Stock Price CAGR

10 Years:7.2

5 Years:5

3 Years:0.7

TTM:-4.8

Return on Equity

10 Years:15.6

5 Years:26.2

3 Years:66.9

last year:50.3

Quarterly Results

Below figures are in Rs. Crores

Particulars	Sep-2024	Dec-2024	Mar-2025	Jul-2025	Sep-2025
Sales	1,70,754	1,35,936	1,28,552	1,22,189	1,05,161
Expenses	63,042	56,557	52,457	45,459	34,856
Operating Profit	1,07,712	79,379	76,096	76,730	70,304
OPM %	63%	58%	59%	63%	67%
Other Income	33,912	31,759	27,333	24,879	18,947
Interest	77,780	58,584	59,248	62,137	53,713
Depreciation	2,345	1,681	1,385	1,277	1,221
Profit Before Tax	61,498	50,873	42,796	38,195	34,318
Tax %	25%	25%	26%	29%	35%
Net Profit	46,149	38,151	31,857	27,296	22,446
EPS in Rs	83	69	58	50	42

Balance Sheet

Below figures are in Rs. Crores

Particulars	Mar-2026	Mar-2025	Mar-2024	Mar-2023	Mar-2022
Share Capital	835	834	834	833	832
Total Reserves	3,76,591	3,33,215	2,80,401	2,30,571	1,89,859
Long-Term Borrowings	---	---	---	---	---
Total Non-Current Liabilities	9,261	6,329	-368	-2,783	-5,083
Other Current Liabilities	64,906	55,031	47,752	46,979	36,606
Short Term Borrowings	59,136	38,045	12,723	7,390	27,082
Total Liabilities	5,59,044	4,75,941	3,78,060	3,15,799	2,84,699
Capital Work in Progress	14,602	23,994	13,510	9,752	12,796
Long Term Loans & Advances	5,066	3,414	5,418	3,559	4,517
Currents Investments	36,728	33,306	44,050	44,495	20,229
Short Term Loans and Advances	40,471	20,043	32,763	9,267	8,441
Total Current Assets	3,00,288	2,50,180	2,48,053	2,04,254	1,77,879
Total Assets	5,59,044	4,75,941	3,78,060	3,15,799	2,84,699
Adjusted Book Value	452	401	337	278	1,146

Positive

(80 to 100)

Neutral

(60 to 79)

Negative

(0 to 59)

The stock has a moderate PE of 23.88, suggesting fair valuation relative to earnings.
Over the last three years, the stock delivered a weak 3-year price CAGR of 0.7%, indicating poor shareholder returns.
The stock carries a low beta of 0.5, suggesting lower volatility than the broader market.
In the last financial year, the company reported an EBITDA of ₹78119 million, reflecting positive operating performance.
In the previous financial year, the company generated revenue of ₹337002 million, indicating a large and established business.

Investment Calculator

Investment Amount:₹

Investment Amount: ₹ 1000000

Current Value: ₹ 950344.5

No. of Shares: 792 (Approx)

Performance:-5%

-49655.5

NIFTY Performance: -1.1%

1 day Top Gainers